These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 22863529

  • 1. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.
    Bioorg Med Chem; 2012 Sep 01; 20(17):5169-80. PubMed ID: 22863529
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2998-3002. PubMed ID: 20382527
    [Abstract] [Full Text] [Related]

  • 3. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7686-98. PubMed ID: 24216091
    [Abstract] [Full Text] [Related]

  • 4. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
    Cai ZW, Wei D, Schroeder GM, Cornelius LA, Kim K, Chen XT, Schmidt RJ, Williams DK, Tokarski JS, An Y, Sack JS, Manne V, Kamath A, Zhang Y, Marathe P, Hunt JT, Lombardo LJ, Fargnoli J, Borzilleri RM.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3224-9. PubMed ID: 18479916
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z, Wang R, Guo R, Hu J, Li R, Zhao Y, Gong P.
    Bioorg Med Chem; 2014 Jul 15; 22(14):3642-53. PubMed ID: 24882675
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
    Lee J, Han SY, Jung H, Yang J, Choi JW, Chae CH, Park CH, Choi SU, Lee K, Ha JD, Lee CO, Ryu JW, Kim HR, Koh JS, Cho SY.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):4044-8. PubMed ID: 22579487
    [Abstract] [Full Text] [Related]

  • 7. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
    Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D'Angelo ND, Germain J, Yang K, Yang Y, Zhang Y, Bellon SF, Whittington DA, Harmange JC, Dominguez C, Kim TS, Dussault I.
    J Med Chem; 2012 Mar 08; 55(5):1868-97. PubMed ID: 22320327
    [Abstract] [Full Text] [Related]

  • 8. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P.
    Bioorg Med Chem; 2013 Jun 01; 21(11):2843-55. PubMed ID: 23628470
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q, Zhao Y, Du X, Chong L, Gong P, Guo C.
    Eur J Med Chem; 2013 Nov 01; 69():77-89. PubMed ID: 24012712
    [Abstract] [Full Text] [Related]

  • 10. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M, Raeppel S, Claridge S, Zhou N, Saavedra O, Isakovic L, Zhan L, Gaudette F, Raeppel F, Déziel R, Beaulieu N, Nguyen H, Chute I, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman JM, Vaisburg A.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6552-6. PubMed ID: 19854051
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y, Ai J, Wang Y, Chen Y, Wang L, Liu G, Geng M, Zhang A.
    J Med Chem; 2011 Apr 14; 54(7):2127-42. PubMed ID: 21405128
    [Abstract] [Full Text] [Related]

  • 12. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
    Liang Z, Ding X, Ai J, Kong X, Chen L, Chen L, Luo C, Geng M, Liu H, Chen K, Jiang H.
    Org Biomol Chem; 2012 Jan 14; 10(2):421-30. PubMed ID: 22108637
    [Abstract] [Full Text] [Related]

  • 13. Discovery of novel type II c-Met inhibitors based on BMS-777607.
    Zhang W, Ai J, Shi D, Peng X, Ji Y, Liu J, Geng M, Li Y.
    Eur J Med Chem; 2014 Jun 10; 80():254-66. PubMed ID: 24792774
    [Abstract] [Full Text] [Related]

  • 14. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L, Zhao J, Zhang B, Lu T, Chen Y.
    Eur J Med Chem; 2018 Apr 25; 150():809-816. PubMed ID: 29602036
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 17. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
    Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P.
    Bioorg Med Chem; 2013 Sep 01; 21(17):5246-60. PubMed ID: 23838381
    [Abstract] [Full Text] [Related]

  • 18. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX, Liu X, Xu S, Tang Q, Duan Y, Xiao Z, Zhi J, Jiang L, Zheng P, Zhu W.
    Eur J Med Chem; 2017 Dec 01; 141():538-551. PubMed ID: 29107421
    [Abstract] [Full Text] [Related]

  • 20. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
    Abbas HA, Al-Marhabi AR, Eissa SI, Ammar YA.
    Bioorg Med Chem; 2015 Oct 15; 23(20):6560-72. PubMed ID: 26420384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.